CURAS — Curasight A/S Share News
0.000.00%
Last trade - 00:00- DKK1.01bn
- DKK983.64m
- -DKK49.68m
Brief: Curasight A/S Says Positive Data Of Utreat In Glioblastoma Provides "Green Light" To Proceed With Next Steps
Brief: Curasight Q4 Operating Loss Widens To DKK 4.4 Mln
Brief: Curasight U.S. Patent Application Relating To Utreat Is Accepted For Grant
Brief: Curasight: Japanese Patent Application Accepted For Grant
Brief: Curasight Q3 Operating Loss Narrows To DKK 218,370
Brief: Curasight: Canadian Patent Application Relating To Utrace Ready For Allowance In Canada